Security Snapshot

NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) Institutional Ownership

CUSIP: 64125C109

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

613

Shares (Excl. Options)

62.11MFull value: 62,109,563 · shares · 30 Sep 2026

Price

$141.84

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0.01%
Share change
+1,915,589
Value change
+$252,371,234
Number of holders
613
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
101,670,800
SEC-reported price per share
$136.98
Insider filing price
$136.98
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock is tracked under CUSIP 64125C109.
  • 613 institutions reported positions in Q3 2026.
  • 6 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 780 to 613 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $17BFull value: $17,003,724,421 · USD · 30 Jun 2026
    to
    $8.82BFull value: $8,819,421,745 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 613 institutions filings for Q3 2026.

Open SEC evidence

Security key

64125C109

13F reference period

Q3 2026

13F holders

613

13D/G owners

6

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
6
Security
NBIX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 12% $1,274,648,181 12,052,271 BlackRock, Inc. 31 Mar 2025
DODGE & COX 5.6% $585,341,834 5,534,624 Dodge & Cox 31 Mar 2025
JPMORGAN CHASE & CO 5.2% -18% $751,807,318 -$147,208,644 5,300,390 -16% JPMORGAN CHASE & CO. 30 Sep 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.2% $692,681,147 5,257,941 Vanguard Capital Management 31 Mar 2026
VANGUARD PORTFOLIO MANAGEMENT LLC 5% $721,049,314 5,083,540 Vanguard Portfolio Management 30 Sep 2026
STATE STREET CORP 4.8% $517,286,649 4,891,137 STATE STREET CORPORATION 31 Dec 2024
As of 30 Sep 2026, 613 institutional investors reported holding
62.11MFull value: 62,109,563 · shares · 30 Sep 2026
shares of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX). This represents 61% of the company’s total
101.67MFull value: 101,670,800 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
37%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Dodge & Cox 5.4% 5,504,578 0.42% $780,769,344
VANGUARD PORTFOLIO MANAGEMENT LLC 5% 5,060,036 0.03% $717,715,506
STATE STREET CORP 4.7% 4,807,975 0.02% $681,963,174
VANGUARD CAPITAL MANAGEMENT LLC 4.5% 4,580,803 0.01% $649,741,098
Vestal Point Capital, LP 2.5% 2,500,000 9.2% $354,600,000
RENAISSANCE TECHNOLOGIES LLC 2.3% 2,300,697 0.44% $326,330,862
GEODE CAPITAL MANAGEMENT, LLC 2.1% 2,127,482 0.02% $301,038,376
Invesco Ltd. 1.2% 1,177,974 0.01% $167,083,831
RTW INVESTMENTS, LP 0.93% 942,684 1.3% $133,710,299
Thrivent Financial for Lutherans 0.81% 824,033 0.19% $116,881,000
DIMENSIONAL FUND ADVISORS LP 0.77% 784,568 0.02% $111,252,618
Swedbank AB 0.74% 754,282 0.09% $106,987,359
BANK OF AMERICA CORP /DE/ 0.73% 741,741 0.01% $105,208,525
Janus Henderson Group Ltd. 0.68% 694,357 0.04% $98,510,883
VANGUARD FIDUCIARY TRUST CO 0.64% 655,591 0.02% $92,989,027
RAYMOND JAMES FINANCIAL INC 0.58% 585,914 0.02% $83,106,043
ARMISTICE CAPITAL, LLC 0.56% 565,251 2.7% $80,175,202
PRIMECAP MANAGEMENT CO/CA/ 0.5% 505,332 0.04% $71,676,291
Hood River Capital Management LLC 0.47% 478,023 0.57% $67,802,782
ALLIANCEBERNSTEIN L.P. 0.47% 475,722 0.02% $67,476,353
Caisse de depot et placement du Quebec 0.43% 437,920 0.09% $62,114,573
Ninety One UK Ltd 0.43% 434,881 0.14% $61,683,525
KBC Group NV 0.41% 418,554 0.12% $59,368,000
Pictet Asset Management Holding SA 0.39% 393,298 0.05% $55,483,866
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.36% 365,851 0.05% $51,892,306

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 62,109,563 $8,819,421,745 +$252,371,234 $141.84 613
2026 Q2 100,968,281 $17,003,724,421 +$207,530,787 $168.54 780
2026 Q1 100,159,474 $13,175,633,880 +$7,733,801 $131.74 701
2025 Q4 99,172,264 $14,056,573,274 +$307,271,827 $141.83 728
2025 Q3 96,958,838 $13,606,200,694 -$264,723,748 $140.38 642
2025 Q2 98,821,219 $12,420,453,326 +$494,184,481 $125.69 578
2025 Q1 95,485,987 $10,559,467,994 +$7,244,935 $110.60 579
2024 Q4 94,376,685 $12,879,887,685 +$230,192,847 $136.50 596
2024 Q3 93,003,458 $10,720,376,398 -$150,384,737 $115.22 570
2024 Q2 93,636,708 $12,887,512,754 +$47,493,212 $137.67 589
2024 Q1 93,218,731 $12,853,312,563 +$116,424,918 $137.92 580
2023 Q4 92,326,586 $12,160,216,767 +$5,244,067 $131.76 545
2023 Q3 92,001,152 $10,350,228,156 +$38,916,412 $112.50 508
2023 Q2 91,514,317 $8,634,655,568 +$37,920,952 $94.30 452
2023 Q1 90,892,702 $9,194,138,307 +$67,286,199 $101.22 481
2022 Q4 90,124,434 $10,754,797,482 +$104,201,709 $119.44 525
2022 Q3 90,489,863 $9,610,613,890 -$33,115,379 $106.21 451
2022 Q2 89,687,591 $8,740,480,340 -$27,492,643 $97.48 426
2022 Q1 90,130,456 $8,447,849,857 +$146,450,381 $93.75 413
2021 Q4 89,152,258 $7,586,914,975 -$142,540,543 $85.17 389
2021 Q3 90,241,905 $8,655,761,280 -$94,927,615 $95.91 390
2021 Q2 91,390,637 $8,892,923,286 -$379,127,377 $97.32 398
2021 Q1 95,118,085 $9,245,217,222 +$547,907,714 $97.25 410
2020 Q4 89,436,431 $8,572,935,331 -$29,252,870 $95.85 394
2020 Q3 89,711,420 $8,625,616,767 -$165,135,029 $96.16 410
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .